NasdaqGS:MRNABiotechs
Moderna (MRNA): Reassessing Valuation After Q3 Earnings Beat and Updated Guidance
Moderna (MRNA) shares were in focus after the company posted third quarter results that topped analyst expectations for both revenue and earnings per share. Despite ongoing revenue declines, the updated guidance and operational adjustments sparked renewed investor interest.
See our latest analysis for Moderna.
After these results, Moderna’s share price rallied more than 13% over the past week, with much of this momentum coming right after its Q3 earnings beat, even as the company narrowed and...